20240041814. USE OF REAGENT FOR DETECTING RETINOL METABOLITE IN PREPARATION OF TOOL FOR DIAGNOSING AND/OR TREATING PNEUMOCONIOSIS simplified abstract (Institute of Basic Medical Sciences of Chinese Academy of Medical Sciences)
USE OF REAGENT FOR DETECTING RETINOL METABOLITE IN PREPARATION OF TOOL FOR DIAGNOSING AND/OR TREATING PNEUMOCONIOSIS
Organization Name
Institute of Basic Medical Sciences of Chinese Academy of Medical Sciences
Inventor(s)
USE OF REAGENT FOR DETECTING RETINOL METABOLITE IN PREPARATION OF TOOL FOR DIAGNOSING AND/OR TREATING PNEUMOCONIOSIS - A simplified explanation of the abstract
This abstract first appeared for US patent application 20240041814 titled 'USE OF REAGENT FOR DETECTING RETINOL METABOLITE IN PREPARATION OF TOOL FOR DIAGNOSING AND/OR TREATING PNEUMOCONIOSIS
Simplified Explanation
The present disclosure describes the use of a reagent for detecting retinol metabolites in the preparation of a tool for diagnosing and/or treating pneumoconiosis, a lung disease caused by the inhalation of dust particles. The disclosure is related to the field of biomedicine.
The abstract states that retinol metabolism disturbance and all-trans retinoic acid (ATRA) deficiency are closely related to the pathogenesis of pneumoconiosis. Therefore, the use of retinol and ATRA as biomarkers for screening pneumoconiosis and in the preparation of diagnostic products is proposed. Additionally, intervention with ATRA can effectively delay the progression of pneumoconiosis, making it a potential medicament for treating the disease.
- Retinol and ATRA can be used as biomarkers for screening pneumoconiosis.
- Retinol and ATRA can be used in the preparation of diagnostic products for pneumoconiosis.
- ATRA can be used as a medicament for treating pneumoconiosis.
Potential applications of this technology:
- Screening and diagnosis of pneumoconiosis using retinol and ATRA biomarkers.
- Development of diagnostic products for pneumoconiosis using retinol and ATRA.
- Treatment of pneumoconiosis using ATRA intervention.
Problems solved by this technology:
- Lack of effective biomarkers for screening and diagnosing pneumoconiosis.
- Limited treatment options for pneumoconiosis.
Benefits of this technology:
- Early detection and screening of pneumoconiosis using biomarkers.
- Improved accuracy and efficiency in diagnosing pneumoconiosis.
- Potential for delaying the progression of pneumoconiosis through ATRA intervention.
Original Abstract Submitted
the present disclosure provides use of a reagent for detecting retinol metabolites in preparation of a tool for diagnosing and/or treating pneumoconiosis, and relates to the technical field of biomedicine. the present disclosure verifies that retinol metabolism disturbance and all-trans retinoic acid (atra) deficiency are closely related to the pathogenesis of pneumoconiosis. therefore, the present disclosure sets forth use of retinol and atra as biomarkers for screening the pneumoconiosis and use thereof in preparation of products related to the diagnosis of the pneumoconiosis; meanwhile, intervention of the pneumoconiosis with the atra can effectively delay the progression of the pneumoconiosis. therefore, the present disclosure first sets forth use of the atra as a medicament for treating the pneumoconiosis.
